Logo (3).png
Immunoassay Market Worth $46.49 Billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®
January 18, 2022 21:30 ET | Meticulous Market Research Pvt. Ltd.
London, Jan. 18, 2022 (GLOBE NEWSWIRE) -- According to a new market research report “Immunoassay Market by Product & Solutions (Immunoassay Kits {ELISA, Rapid Tests}, Immunoassay Platform,...
Graphical Research.jpg
In Vitro Diagnostics (IVD) Market Trends 2022 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research
January 18, 2022 07:00 ET | Graphical Research
Pune, India, Jan. 18, 2022 (GLOBE NEWSWIRE) -- The global in vitro diagnostics (IVD) market size is estimated to witness lucrative growth during the forecast timeline owing to the rising...
SDI Labs and CLEARED4 Team Up to Deliver Global Tele-Proctoring Services With HealthVu
January 13, 2022 11:30 ET | SDI Labs, Inc.
GARDEN GROVE, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- SDI Labs, a minority-owned, high-complexity diagnostics lab that empowers patients with systems-based solutions for optimal health outcomes,...
Icosavax_Logo.jpg
Icosavax Provides Corporate Update and Anticipated Milestones for 2022
January 07, 2022 08:00 ET | Icosavax, Inc.
SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax_Logo.jpg
Icosavax Appoints Dr. John Shiver to Board of Directors
January 05, 2022 08:00 ET | Icosavax, Inc.
SEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax_Logo.jpg
Icosavax to Participate in Upcoming Investor Conferences
November 11, 2021 16:22 ET | Icosavax, Inc.
SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
VIR_logo_large.jpg
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET | Vir Biotechnology, Inc.
– To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide – – In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collaboration...
VIR_logo_large.jpg
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021
October 21, 2021 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter...
AMR Logo.png
Antimicrobial Susceptibility Testing Market Predicted to Reach $4.73 Billion by 2030, Exclusive Report by Allied Market Research
October 12, 2021 03:18 ET | Allied Market Research
Portland, OR, Oct. 12, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global antimicrobial susceptibility testing market generated $3.04 billion in 2020,...
7 Hills Logo.png
Texas Heart Institute, University of Texas Medical Branch (UTMB) and 7 Hills Pharma Pioneer Significant Vaccine Research
October 01, 2021 14:59 ET | 7 Hills Pharma
HOUSTON, TX., Oct. 01, 2021 (GLOBE NEWSWIRE) -- The Texas Heart Institute has announced that a research team led by its Vice President for Research Dr. Darren Woodside and Dr. Peter Vanderslice, of...